{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["65(1)"],"submitter":["Iaccarino L"],"pubmed_abstract":["Objective
To assess efficacy of voclosporin (VCL) from a retrospective, observational, clinical-practice-based, nationwide multicentre study of patients with LN.Methods
Patients with biopsy-proven LN were enrolled from November 2023 to April 2025 from tertiary Rheumatology and Nephrology Italian Centres. Those with uncontrolled arterial hypertension and eGFR < 30 ml/min/1.73 m2 were excluded. Patients received oral 23.7 mg VCL BID and MMF 1 g BID. Glucocorticoid schedule followed existing recommendations for LN management. Clinical and serological data were collected at SLE diagnosis, VCL initiation and after 6, 12, 24 and 48 weeks. Complete renal response (CRR) was defined as eGFR ≥ 60 ml/min/1.73 m2, <20% eGFR decrease from baseline, 24-h proteinuria <0.5 g/day, no rescue"],"journal":["Rheumatology (Oxford, England)"],"pagination":["keaf654"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12784457"],"repository":["biostudies-literature"],"pubmed_title":["Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS (Voclosporin in Real Life Setting Study) experience."],"pmcid":["PMC12784457"],"pubmed_authors":["Di Gregorio A","Bortoluzzi A","De Marchi G","Picciotto D","Moroni G","Gozza F","Calatroni M","Marongiu G","Fredi M","Esposito P","Allinovi M","Zen M","Fenaroli P","Tomietto P","Orsolini G","Ruzzon F","Buscetta G","Silvagni E","De Angelis R","Doria A","Santoro D","Pazzola G","Franceschini F","Quartuccio L","Ferio C","Emmi G","Iaccarino L","Vesentini F"],"additional_accession":[]},"is_claimable":false,"name":"Early antiproteinuric effect of voclosporin in patients with LN in a real-life setting: preliminary results from the VoRLiSS (Voclosporin in Real Life Setting Study) experience.","description":"Objective
To assess efficacy of voclosporin (VCL) from a retrospective, observational, clinical-practice-based, nationwide multicentre study of patients with LN.Methods
Patients with biopsy-proven LN were enrolled from November 2023 to April 2025 from tertiary Rheumatology and Nephrology Italian Centres. Those with uncontrolled arterial hypertension and eGFR < 30 ml/min/1.73 m2 were excluded. Patients received oral 23.7 mg VCL BID and MMF 1 g BID. Glucocorticoid schedule followed existing recommendations for LN management. Clinical and serological data were collected at SLE diagnosis, VCL initiation and after 6, 12, 24 and 48 weeks. Complete renal response (CRR) was defined as eGFR ≥ 60 ml/min/1.73 m2, <20% eGFR decrease from baseline, 24-h proteinuria <0.5 g/day, no rescue","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T13:09:47.502Z","creation":"2026-05-30T03:11:21.409Z"},"accession":"S-EPMC12784457","cross_references":{"pubmed":["41386258"],"doi":["10.1093/rheumatology/keaf654"]}}